Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting

This publication has 161 references indexed in Scilit:

• 751 The safety and efficacy of viramidine® plus pegylated interferon alpha-2B versus ribavirin plus pegylated interferon alpha-2B in therapy-naïve patients infected with HCV: Phase 3 results
  Journal of Hepatology, 2006
• 623 Safety and pharmacokinetics of NM107 following intravenous infusion of escalating doses in healthy volunteers: Determination of absolute oral bioavailability of valopicitabine (NM283)
  Journal of Hepatology, 2006
• LIVER TARGETING OF HEPATITIS-B ANTIVIRAL LAMIVUDINE USING THE HEPDIRECT™ PRODRUG TECHNOLOGY
  Nucleosides, Nucleotides and Nucleic Acids, 2005
• Direct Evidence for Peptide Transporter (PepT1)-Mediated Uptake of a Nonpeptide Prodrug, Valacyclovir
  Biochemical and Biophysical Research Communications, 1998
• Valacyclovir: A Substrate for the Intestinal and Renal Peptide Transporters PEPT1 and PEPT2
  Biochemical and Biophysical Research Communications, 1998
• Molecular cloning and tissue distribution of rat peptide transporter PEPT2
  Biochimica et Biophysica Acta (BBA) - Biomembranes, 1996
• Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy
  Antiviral Research, 1995
• Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus— and cytomegalovirus-seropositive patients
  Clinical Therapeutics, 1995
• Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells
  Biochemical and Biophysical Research Communications, 1991
• Phase I study of oral doxifluridine using two schedules
  European Journal of Cancer and Clinical Oncology, 1989